NCT04199260 - Investigation to Evaluate PAPILOCARE® Gel Effect on Normalization of Cervix Cytological Alterations Caused by HPV. | Biotech Hunter

Enrollment

263

Participants

Timeline

Start Date

May 20, 2018

Primary Completion Date

February 18, 2021

Study Completion Date

February 18, 2021

Conditions

HPV InfectionLesion Cervix

Interventions

DEVICE

papilocare vaginal gel

Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution

Trial Locations (9)

28001

Gabinete Médico Velázquez, Madrid

28040

Hospital Clínico San Carlos, Madrid

29004

Hospital Quirón Málaga, Málaga

41720

Instituto Palacios de Salud y Medicina de la Mujer, Madrid

03010

Hospital General Universitario de Alicante, Alicante

08017

Women´s Health Institute, Barcelona

08041

Hospital de la Santa Creu i Sant Pau, Barcelona

Unknown

Clínica Diatros, Barcelona

MD Anderson, Madrid